In the context of cancer, PD-L1 is usually highly expressed on tumor cells, thereby evading immune surveillance, but it has also been reported that high PD-L1 expression can make tumor cells more sensitive to PD-1/PD-L1 inhibitors. This evidence concerns the gene CD274 and cancer.